{"name":"Neumora Therapeutics, Inc.","slug":"neumora","ticker":"NMRA","exchange":"NASDAQ","domain":"neumoratx.com","description":"Neumora Therapeutics, Inc. (NMRA) is a CNS-focused biotech company. The company's top drugs are in development for neurological disorders. Neumora Therapeutics is a relatively new company, and its market position is evolving.","hq":"Boston, MA","founded":0,"employees":"","ceo":"Henry O. Gosebruch","sector":"CNS Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$2.1B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NMRA-335140","genericName":"NMRA-335140","slug":"nmra-335140","indication":"Major depressive disorder","status":"phase_3"}]}],"pipeline":[{"name":"NMRA-335140","genericName":"NMRA-335140","slug":"nmra-335140","phase":"phase_3","mechanism":"NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects.","indications":["Major depressive disorder"],"catalyst":""}],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"Neumora Therapeutics Announces FDA Clearance of IND for NMRA-101","summary":"Neumora Therapeutics received FDA clearance to initiate a Phase 1 clinical trial for NMRA-101, a potential treatment for a neurological disorder.","drugName":"NMRA-101","sentiment":"positive"},{"date":"2022-11-15","type":"deal","headline":"Neumora Therapeutics Raises $75M in Series B Financing","summary":"Neumora Therapeutics announced a $75 million Series B financing round to support the development of its CNS pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1fRkZHSE5YQ09OSWg1eGtRNDZzeW1yZ0JaQTdGNzdvY3hYR0N0aVNSTDNYMmdiX0pNYVNNZ1l0R0RJb1lzWTlaVUFMR3RwQV80TW04ZjdQZmNhSmxvYUNEWHhhZTF3U1F6SHQ3cHR3?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan","headline":"If You Invested $1,000 in Neumora Therapeutics Inc (NMRA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxOdTAwVzI1bFk1MXpxU25zcmQzRFB2cElVMm9peGZJcy1yTkhkRG43VksxUEZqa2ZRS01feXpxS1Q5ODlpQ0lBdDViME1YS21OMmhTNVA2ZFMxa2tYRU5sd1ZYWFloZ2RQX1hNZ1N2eXg0dUNYbEZMQTExNk5kZHRIWVFrT0htU0dsTVVvVVBfRVV5VnVkdm9YUnRMTTFCd3pWMzBfZVBKOEtCN3NzWEpBYW1uWmNiNVQxUW1UTEQxWjlBY1Nhc0NUVldPcVpMeEVCMG11ZXNiZExxUzlBbjBUdFZZWnlvRWhQM3NycHhDQ0pxdU9ISWVINjVmMWRzTkpPNTNSUFlrM3VhX1VmTVV5X19zX0hVZ3V4cnUxRmFDSjllMklxOTVV?oc=5","date":"2026-04-05","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail","headline":"Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (AN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxQTzhuOWVTYWRqeWlud0VNVmdDa3V0MGhoU2ZWUmsxbFdtbjZ3Rk5tN2M2OXpuLThGWXh6NmdXUnYza3hTV0stM2VRWE5aMmV2MTVVU0cycVc4VFJnU25NUDVuUkNVZm9aaUZZMWFFak5mM1RMdW1ROExjTFFZa1lFNkFBam9jaWc1aXhBVDFpdTdmb2xzNFVOSTE3aHpEMzRIUjdKcTdlNHg2aExDZ0NsbG5PLVVCeUF3SjN4Nk40ZDM0ZjV5Ti11ZTRrTWxvSWtnTUNVdnFXRVlpZ2ZyVm1GVlJCQ3Y3UFNiM3ZUMmd1V21JR3I2ZmZxN3IySWZVRTBZTnNRTllpNUh2VnZIaGc?oc=5","date":"2026-04-01","type":"pipeline","source":"globenewswire.com","summary":"NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - globenewswire.com","headline":"NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNSzI4OGlCa0QtWlRkYkJMaGtFV0ttSTNlaWZmN2VUdHhJRlBrWERrLUVrZUVWbFhEZV8yRzVNanBrd1ZIY0lXdWxDbWY2YWk2U2JweEdjMVExeHl5WE5pZjdFSFA0bDl3bUhTREl3b01HWGJoR3FZSVRWTm1ORXpWMG5ReFFqalhGMWs5ZWVSMF9RdHJQT1c5VFlnbVBVZkhaRkw0LXJvRTZPd3F2X1NxNA?oc=5","date":"2026-03-30","type":"pipeline","source":"Seeking Alpha","summary":"Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA) - Seeking Alpha","headline":"Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-11","type":"pipeline","source":"simplywall.st","summary":"Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative? - simplywall.st","headline":"Does Neumora Therapeutics’ (NMRA) Guggenheim Spotlight Recast Its Core Neuroscience Investment Narrative?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-09","type":"pipeline","source":"simplywall.st","summary":"3 Promising Penny Stocks With Market Caps Up To $400M - simplywall.st","headline":"3 Promising Penny Stocks With Market Caps Up To $400M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOeE5XbDlnMlA2NTljVWF1UUxjbWVkc0ZHTkNncHZvX1NQU1I5Tm1rVk16R0RCR0lqUnBMWnJyTzc3Y2hIUXV4ZFZhVWlVS3VYZEhfVXB4QXpBaFNfUVZ2dGZYWU9DekpfaGVaM2ZLem9MeUt4YUJyX25tSGxQQzI2d1g0VGRBLUsxSkFrWDh5LWZsZzZuRy1GXzMtQ2hYMlJQZzJKdTduMXVDREJCN0tBWUI5TzR0S3FlclZVSWpadHF3YkNRUkNlYlVjaVYwcng2b0JNRTZ0eTRQNTVjZkNqaWlmVWsyMGhyNjNfSGZMR2htVGdjbFZtd3lGU1JRU3NCdlNVRzI2VUlIeHN1MHpfVWUwUUUzOUt0aEludkRsYkZ0cVBkZUdESndaUTlKZk0?oc=5","date":"2026-01-06","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Neumora Therapeutics, Inc. (NMRA) and Arcellx Inc (ACLX) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Neumora Therapeutics, Inc. (NMRA) and Arcellx ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQeEpVWnk2a3Y1WTd0UlppVmw4dGtLWDJmTWxZRHpmbFlTREVfd3RfaDlsa3NSQm44UDZUYzRWa1ZRTmVpaTQyMXVuX1l1QzlYTmZURkdzV09kRUdncUJrQTd1dk5ZTURBSFQ4WDd6Mzl3MzQyd2YtNmtfTmhXVWs2eU52N0FTSjhhMi1ad0hMbl81aFBEMnR3?oc=5","date":"2025-10-31","type":"pipeline","source":"Yahoo Finance","summary":"Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity - Yahoo Finance","headline":"Neumora Therapeutics (NMRA): Evaluating Valuation Following Dual Pipeline Advances in Psychiatry and Obesity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNNjZZMUNIaXdibklhZExlbUY3b1ZINEJkdGFHZUtLeVZ5MjhmLWVXUHB4R2hxSDRXbjh1LWJIR3h5TmlqVGxRSDVqVGgyNTRhS0FUNVRLVFF1MjFxbFFlS0FVMW9KVlk2MU1MaEM5S3hHRjRVSEdha2ZNSDd4SE9IUnFxejdhU2lUTE1XRA?oc=5","date":"2025-08-19","type":"trial","source":"Yahoo Finance","summary":"Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861 - Yahoo Finance","headline":"Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE4zdnptN2gxMlBkY1p2MzU1aDFJQl9wUkt4WTQzSEx3VWlDNDIwZzUzYzFicTE3Umw0YWFUWHhGTi10czRKdm8tdzJTd3VMQ3lGanRuVjFuYVVrMVBu?oc=5","date":"2025-04-02","type":"pipeline","source":"TradingView","summary":"NMRA Stock Price and Chart — NASDAQ:NMRA - TradingView","headline":"NMRA Stock Price and Chart — NASDAQ:NMRA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBTaHZydlpBcGJ3MU5aVkVzaHp3anBYZ2V6X0EwN2RJTG5qQmtCSTFyakRiYndDQ3g5R2dVcmVkV0tQa0FlMXBVLXBjVlA1UElUdnNBTkE5ZHhwMjZNcjY3VWt4a2FFQlU5MTJVZ20ybWdFOTNENzdnUw?oc=5","date":"2024-06-02","type":"pipeline","source":"Zacks Investment Research","summary":"What is the current Price Target and Forecast for Neumora Therapeutics, Inc. (NMRA) - Zacks Investment Research","headline":"What is the current Price Target and Forecast for Neumora Therapeutics, Inc. (NMRA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5NS1dFYmdCU1RzbXhpaE8wSTNtTGdXcXpzUVBINzRGUGpSTW4wQ3FxNFRVblZHaGdaN0NCSXlyM2VRbXFlb0tXS18wRHJvVmR3?oc=5","date":"2023-12-18","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":4,"keyCompetitors":["Biogen","Pfizer","Eli Lilly"],"therapeuticFocus":["Neurological Disorders","CNS Diseases"],"financials":null,"yahoo":null}